Pure-play biosimilars developer Alvotech intends within the next seven months to finalise sales, marketing and distribution alliances with a few strategic parents to commercialize the pipeline of seven monoclonal antibody (mAb) biosimilars that the company plans to bring to market from 2020.
Alvotech Advances Partnerships To Take Pipeline Global
By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.
